Two multi-year collaborative agreements were recently established by Amgen and the University of Texas MD Anderson Cancer Center to advance the development of…
Most U.S. residents are unaware there are shortages in the availability of cancer drugs, such as those for multiple myeloma, a type of cancer…
Janssen has decided to discontinue a Phase 1 trial assessing Darzalex (daratumumab) in combination with JNJ-63723283 — an anti-PD-1 antibody — in multiple myeloma patients, …
Researchers in Canada are studying how to reduce the risks associated with the treatment of multiple myeloma by improving the safety and efficacy of…
Stand Up to Cancer (SU2C) recently awarded $10 million to a SU2C Dream Team that wants to move the treatment of multiple myeloma from…
A Phase 1 clinical trial testing therapy candidate STRO-001 for lymphoma and myeloma has started treating its first patients, announced Sutro Biopharma, the therapy’s…
As part of its $15 million Immunotherapy Initiative, the Multiple Myeloma Research Foundation (MMRF) recently awarded $7 million in funding to three innovative research…
AbbVie and the International Myeloma Foundation are collaborating to study the role of a genetic mutation — the t(11;14) translocation — in multiple myeloma treatments…
To raise awareness of multiple myeloma and funding for research, 18 patients, caregivers, and healthcare professionals have embarked on a challenging ascent to Mount Everest…
As UT Southwestern and Celgene Corporation join efforts to launch a new clinical trial to evaluate a chimeric antigen receptor T-cell therapy,…